07.16.21
Headquarters: Leverkusen, Germany
twitter.com/Bayer
www.bayerpharma.com
Headcount: 99,538
Year Established: 1971
Pharma Revenues: $14,037 (-6%)
Loss: $12,881 (n/m)
R&D: $3,369 (+11)
TOP SELLING DRUGS
Pharma sales for Bayer were $14 billion, down 6% for the year. The company is focused on prescription products, for cardiology and women’s healthcare, as well as specialty therapeutics in the areas of oncology, hematology, ophthalmology and cell and gene therapy.
Bayer’s near- to medium-term growth is driven by key products such as Xarelto and Eylea, and will be further fueled by several promising late-stage R&D candidates, such as finerenone, and recently launched products, such as Verquvo and Nubeqa.
Last year, Bayer’s Pharmaceuticals Division invested heavily in external innovation, concluding more than 25 collaboration agreements and acquisitions. It took a major step forward in particular with the acquisition of Asklepios BioPharmaceutical (AskBio). This transaction, together with the acquisition of BlueRock Therapeutics in 2019, has put the company among the leading players in the promising and rapidly expanding area of cell and gene therapies.
Another fundamental element of the company’s new cell and gene therapy strategy is the partnership with Atara Biotherapeutics, which strengthens its cell therapy pipeline.
Bayer is also invested in external growth with the acquisition of KaNDy Therapeutics, which further expands its development portfolio in women’s healthcare. KaNDy’s recently completed Phase IIb for a non-hormonal oral compound, with positive data for the treatment of frequent symptoms of menopause.
Bayer also purchased an exclusive license from Systems Oncology for preclinical oral drug candidate ERSO, a treatment for women with metastatic estrogen receptor-positive breast cancer.
Through Leaps by Bayer, an investment in Metagenomi Technologies aims to find ways to cure genetic diseases through novel gene editing technologies. It also invested in Vesigen Therapeutics, with the goal of focusing modern cell and gene therapies on specific cells in the body, which is considered an especially critical supporting technology. Furthermore, the company has joined a financing round for Senti Biosciences, Inc., a U.S. biotech company which is a leader in the use of synthetic biology to engineer gene circuits to improve cell and gene therapy products.
In the area of immuno-oncology, Bayer invested in Triumvira Immunologics Inc., a company in the field of T-cell therapy. In microbiome research, it invested in Azitra Inc., with the aim of assembling a joint platform to develop novel antimicrobial dermatological products. Leaps by Bayer also invested in the foundation and incubation of early-stage biotech companies as part of the Israeli company FutuRx Ltd.
Most recently, amid sliding sales for prostate cancer drug Xofigo, Bayer bolstered its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics and subsidiary PSMA Therapeutics. Bayer picked up exclusive rights to two investigational therapies in prostate cancer.
twitter.com/Bayer
www.bayerpharma.com
Headcount: 99,538
Year Established: 1971
Pharma Revenues: $14,037 (-6%)
Loss: $12,881 (n/m)
R&D: $3,369 (+11)
TOP SELLING DRUGS
Drug | Indication | 2020 Sales | (+/-%) |
Xarelto | atrial fibrillation | $5,472 | 9% |
Eylea | macular degeneration | $2,991 | -1% |
Mirena | women’s health | $1,310 | -12% |
Kogenate | Hemophilia A | $1,031 | -4% |
YAZ/Yasmin | Contraception | $812 | -2% |
Nexavar | Oncology | $774 | -10% |
Aspirin | Cardio Pain and cardio | $774 | 10% |
Adempas | Cardiology | $761 | 50% |
Adalat | Cardiology | $743 | -8% |
Stivarga | Oncology | $576 | 16% |
Pharma sales for Bayer were $14 billion, down 6% for the year. The company is focused on prescription products, for cardiology and women’s healthcare, as well as specialty therapeutics in the areas of oncology, hematology, ophthalmology and cell and gene therapy.
Bayer’s near- to medium-term growth is driven by key products such as Xarelto and Eylea, and will be further fueled by several promising late-stage R&D candidates, such as finerenone, and recently launched products, such as Verquvo and Nubeqa.
Last year, Bayer’s Pharmaceuticals Division invested heavily in external innovation, concluding more than 25 collaboration agreements and acquisitions. It took a major step forward in particular with the acquisition of Asklepios BioPharmaceutical (AskBio). This transaction, together with the acquisition of BlueRock Therapeutics in 2019, has put the company among the leading players in the promising and rapidly expanding area of cell and gene therapies.
Another fundamental element of the company’s new cell and gene therapy strategy is the partnership with Atara Biotherapeutics, which strengthens its cell therapy pipeline.
Bayer is also invested in external growth with the acquisition of KaNDy Therapeutics, which further expands its development portfolio in women’s healthcare. KaNDy’s recently completed Phase IIb for a non-hormonal oral compound, with positive data for the treatment of frequent symptoms of menopause.
Bayer also purchased an exclusive license from Systems Oncology for preclinical oral drug candidate ERSO, a treatment for women with metastatic estrogen receptor-positive breast cancer.
Through Leaps by Bayer, an investment in Metagenomi Technologies aims to find ways to cure genetic diseases through novel gene editing technologies. It also invested in Vesigen Therapeutics, with the goal of focusing modern cell and gene therapies on specific cells in the body, which is considered an especially critical supporting technology. Furthermore, the company has joined a financing round for Senti Biosciences, Inc., a U.S. biotech company which is a leader in the use of synthetic biology to engineer gene circuits to improve cell and gene therapy products.
In the area of immuno-oncology, Bayer invested in Triumvira Immunologics Inc., a company in the field of T-cell therapy. In microbiome research, it invested in Azitra Inc., with the aim of assembling a joint platform to develop novel antimicrobial dermatological products. Leaps by Bayer also invested in the foundation and incubation of early-stage biotech companies as part of the Israeli company FutuRx Ltd.
Most recently, amid sliding sales for prostate cancer drug Xofigo, Bayer bolstered its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics and subsidiary PSMA Therapeutics. Bayer picked up exclusive rights to two investigational therapies in prostate cancer.